Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + levofloxacin
- Development stage
- Phase 4
- Lead developer
- Daiichi Sankyo
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Amoxicillin + levofloxacin is a combination antibiotic therapy used primarily for the treatment of Helicobacter pylori infections. This combination is typically administered with a proton pump inhibitor as part of triple therapy regimens. Amoxicillin is a penicillin-type antibiotic that inhibits bacterial cell wall synthesis, while levofloxacin is a fluoroquinolone antibiotic that works by inhibiting bacterial DNA topoisomerase II. The combination provides broad-spectrum coverage against various bacterial pathogens.
- Other names
- LVX + AMX
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)PBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on amoxicillin + levofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxicillin + levofloxacin.